Skip to main content
Article thumbnail
Location of Repository

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy

By Peixun Zhou, Sophia Hatziieremia, Moira A. Elliott, Linda Scobie, Claire Crossan, Alison M. Michie, Tessa L. Holyoake, Gavin W. Halbert and Heather G. Jorgensen

Abstract

Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis. As a result, patients are unlikely to be cured owing to the persistence of leukemic quiescent stem cells (QSC) capable of initiating relapse. Previously, we have reported that intracellular levels of imatinib in primary primitive CML cells (CD34<sup>+</sup>38<sup>lo/−</sup>), are significantly lower than in CML progenitor cells (total CD34<sup>+</sup>) and leukemic cell lines. The aim of this study was to determine if potentially sub-therapeutic intracellular drug concentrations in persistent leukemic QSC may be overcome by targeted drug delivery using synthetic Low Density Lipoprotein (sLDL) particles. As a first step towards this goal, however, the extent of uptake of sLDL by leukemic cell lines and CML patient stem/progenitor cells was investigated. Results with non-drug loaded particles have shown an increased and preferential uptake of sLDL by Bcr-Abl positive cell lines in comparison to Bcr-Abl negative. Furthermore, CML CD34<sup>+</sup> and primitive CD34<sup>+</sup>38<sup>lo/−</sup> cells accumulated significantly higher levels of sLDL when compared with non-CML CD34<sup>+</sup> cells. Thus, drug-loading the sLDL nanoparticles could potentially enhance intracellular drug concentrations in primitive CML cells and thus aid their eradication

Topics: RC0254
Publisher: Elsevier
Year: 2010
OAI identifier: oai:eprints.gla.ac.uk:44379
Provided by: Enlighten

Suggested articles

Citations

  1. (1986). A receptor-mediated pathway for cholesterol homeostasis (Nobel lecture), doi
  2. (2002). A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro,
  3. (2006). Alteration in lipid profile in patients of chronic myelold leukemia before and after chemotherapy, doi
  4. (2006). BCR-ABL activity and its response to drugs can be determined in CD34(+) CML stem cells by CrkL phosphorylation status using flow cytometry, doi
  5. Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation,
  6. (2005). Brain tumor stem cells, doi
  7. (2008). CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate, doi
  8. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abi (vol 7, pg 129, doi
  9. (2006). Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction, doi
  10. (1984). Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation, doi
  11. (2002). Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines, doi
  12. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia,
  13. (2006). Functional ABCG2 is overexpressed on primary CML CD34(+) cells and is inhibited by imatinib mesylate, doi
  14. (2007). Intergroupe Francais Leucemies, Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years, doi
  15. (1999). Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia, doi
  16. (2005). Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro, doi
  17. (1981). Low density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms,
  18. (1978). Low-density lioprotein (LDL) receptor activity in human acute myelogenous leukaemia cells,
  19. (1994). Low-Density-Lipoprotein as a Vehicle for Targeting Antitumor Compounds to Cancer-Cells, doi
  20. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity, doi
  21. (2009). Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters, doi
  22. (2007). Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis doi
  23. (2006). OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib, Blood, doi
  24. (2009). Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells, doi
  25. (2003). Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment, doi
  26. (2001). Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences, doi
  27. (2002). Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro, doi
  28. (2005). Prospective identification of tumorigenic prostate cancer stem cells, doi
  29. (2006). Purification and unique properties of mammary epithelial stem cells, doi
  30. (2006). Receptor dependent cellular uptake of synthetic low density lipoprotein by mammalian cells in serum-free tissue culture, doi
  31. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, doi
  32. (1977). Structure and interactions in human plasma Low Density Lipoprotein., doi
  33. (2005). Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture, doi
  34. (2007). Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme, doi
  35. (2007). Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme, doi
  36. (2009). Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells, doi
  37. (1984). The Incorporation of Lipid-Soluble Antineoplastic Agents into Microemulsions Protein-Free Analogs of Low-Density Lipoprotein, doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.